Incyte Corporation (INCY) Stock

Understand Incyte Corporation: how it makes money

Incyte develops and sells specialty biopharmaceuticals for blood cancers, solid tumors, and immunology in the US and internationally, earning revenue from branded drug sales and licensing royalties. Jakafi alone drives 58% of quarterly sales, while Iclusig, Pemazyre, and Opzelura broaden the mix across hematology, oncology, and dermatology.

Jakafi's 58% revenue share absorbs the fixed R&D and SG&A base, so each incremental dollar from Opzelura, new launches, or the late-stage pipeline flows through at roughly 24% operating margin with 92% gross margin protection.

Business quality (Solid): Solid: a 92% gross margin on a concentrated, branded product base converts into 24% operating leverage, but single-asset dependence (Jakafi at 58%) makes the model vulnerable to one competitor's entry.

Valuation: Trades at 20× trailing earnings · $25.6B market cap.

Bull case

• Pipeline rebuilds the 2030 base: Management targets $3B to $4B in net sales from the business excluding Jakafi by 2030, implying the current ~$540M non-Jakafi base needs to roughly 5x in six years. Achieving that would make Jakafi a declining share of a much larger pie.
• Formulary gains unlock Opzelura: Opzelura is on track for 50% to 70% formulary coverage by year-end, which directly lifts refill persistence and patient retention for the $140M quarterly product.
• Growth lags the valuation: At a P/E of 19.8x with revenue growing 21% YoY, the multiple sits below the rule-of-48 threshold, suggesting the market is not yet pricing in the pipeline optionality (10 data readouts in H2 FY26).

Bear case

• Net pricing headwind erodes margin: Management flagged that pricing and reimbursement dynamics require disciplined gross-to-net management, meaning the 92% gross margin could compress as PBM rebates and government pressure intensify on Jakafi's dominant position.
• Pipeline gaps ahead of catalysts: The Phase 3 program 058 was discontinued with no data expected this year, removing one near-term revenue option. With 10 readouts planned in H2, a single negative readout could hit sentiment hard on a name where 58% of revenue rides one asset.
• FDA path keeps Jakafi in limbo: The myelofibrosis regulatory pathway still depends on completing FDA conversations around trial design endpoints, creating a binary risk to extending Jakafi's label and preserving its growth runway.

Related Companies (Business Services; 8 comparable business services companies)

• Charles River Laboratories International, Inc. (CRL)
• Medpace Holdings, Inc. (MEDP)
• IQVIA Holdings Inc. (IQV)
• CoreWeave, Inc. Class A Common Stock (CRWV)
• ADT Inc. (ADT)
• Twilio Inc. (TWLO)
• TriNet Group, Inc. (TNET)
• Amdocs Limited (DOX)